Cell Types | Classification | Molecular markers | Functions or prognostic values | Study | |
---|---|---|---|---|---|
Breast cancer cells | All | ERα−HER2−Survivinhigh | Significantly correlated with resistance to neoadjuvant chemotherapy | Wagner et al. [26] | |
TNBC | “cluster 2” | GLTP, SPTLC1, S1PR1, GPI/AMF, F11R, CCL20, CCL22 | Significantly correlated with worse survival outcomes of the TNBC | Karaayvaz et al. [30] | |
CAFs | myCAF | “cluster 0, 3, 4, 6, 7” | Extracellular matrix (ECM) proteins; TGFβ signaling pathway; wound healing; IFNαβ; acto-myosin pathway | Significantly correlated with an immunosuppressive environment | Kieffer et al. [51] |
mCAF | Glycoproteins (Dcn, Lum, and Vcan); structural proteins (Col14a1); matricellular proteins (Fbln1, Fbln2, and Smoc); Matrix-modifying enzymes (Lox and Loxl1); CXCL14; Fibulin-1; PDGFRα | The relative number of mCAFs decreased during tumor progression | Bartoschek et al. [43] | ||
vCAF | Notch3, Epas1, Col18a1, Nr2f2, Cspg4, Rgs5, Pdgfrb, Des, Cd248 | An independent risk factor of distant metastasis | Bartoschek et al. [43] | ||
dPVL | Perivascular markers including MCAM (CD146), CAV1, RGS5, MYH11, TAGLN (SM-22-Alpha); ACTA2 (⍺-SMA), PDGFRB, THY1 (CD90), S100A4 (FSP-1), ITGB1 (CD29) | Strongly correlated with CTL exclusion; A potential biomarker for identifying patients suitable for vessel-targeted therapeutic strategies | Wu et al. [58] | ||
iCAF | CXCL12, CD40, B7H3, DPP4, CD73, C5, IL6,TGFβ | Strongly associated with CTL dysfunction and myeloid cells regulation | Wu et al. [58] | ||
Immune cells | CD8 + T cells | TRM | ITGAE, CD103, GZMB, perforin (PRF1), HAVCR2 (TIM3), PDCD1 (PD1), CTLA4, TIGIT and LAG3; low expression of KLF2, SELL, S1PR1, S1PR5 and KLRG1; | Associated with improved prognosis and longer OS in early-stage TNBC; A predictor of a better response to anti-PD-1 therapy | Savas.et al. [73] |
Myeloid cells | TAM | PD-L1+ CD64highHLA-DRhigh | Associated with tumor aggression | Wagner et al. [26] | |
B cell | ICOSL+ | Correlated with improved neoadjuvant chemotherapy effect; An independent positive prognostic factor for DFS and OS of breast cancer. | Lu et al. [132] |